Seer Board Rejects Takeover Bid, Affirms Independent Strategy

Seer ( (SEER) ) has issued an update.

On April 27, 2026, Seer’s board unanimously rejected a revised unsolicited, non-binding takeover proposal from the Radoff-JEC Group to acquire all Class A shares for $2.35 per share in cash plus a contingent value right. The board said the offer significantly undervalues Seer, implying an equity value below the company’s cash, equivalents and investments, and ignores the value of its proteomics platform, technology leadership and standalone growth outlook.

Directors highlighted Seer’s strategy of building a distinct, unbiased proteomics market from the ground up, leveraging its Proteograph suite, growing customer adoption and population-scale projects such as Singapore’s SGK100 study. The decision signals Seer’s intent to remain independent as it seeks to capitalize on its IP portfolio, lighthouse biobank accounts and AI-driven biology positioning, while the board also prepares to address dissident director nominees from the Radoff-JEC Group in the upcoming 2026 annual meeting process.

The most recent analyst rating on (SEER) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.

Spark’s Take on SEER Stock

According to Spark, TipRanks’ AI Analyst, SEER is a Neutral.

The score is held back primarily by persistent losses and cash burn (despite improving margins) and bearish technicals with the stock trading below major moving averages. Conservative 2026 guidance and funding uncertainty add pressure, partially offset by low leverage, disciplined expense reductions, and management’s expectation of continued free-cash-flow improvement supported by its stated cash position.

To see Spark’s full report on SEER stock, click here.

More about Seer

Seer, Inc., listed on Nasdaq as SEER, operates in the life sciences and proteomics industry, providing deep, unbiased proteomic insights for research use. Its flagship Proteograph Product Suite combines engineered nanoparticles, automation instruments, consumables and analytical software to enable scalable, high-throughput proteomic analysis, targeting population-scale studies and AI-driven biology applications.

The company focuses on expanding adoption through large biobanks and cohort studies, positioning its platform as a preferred solution in the growing proteomics market. Seer’s competitive moat is underpinned by more than 80 peer-reviewed publications, substantial patent coverage and a growing installed base that supports broader market penetration and long-term data-driven value creation.

Average Trading Volume: 375,204

Technical Sentiment Signal: Sell

Current Market Cap: $111.1M

Find detailed analytics on SEER stock on TipRanks’ Stock Analysis page.